패혈증 진단 시장 : 제품 유형, 기술, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Sepsis Diagnostic Market is projected to grow by USD 1,744.59 million at a CAGR of 8.35% by 2032.

Sepsis Diagnostic Market Introduction

Sepsis diagnostics are becoming a core priority for hospitals, laboratories, and health systems because sepsis remains one of the most time-sensitive and high-mortality conditions in acute care. The World Health Organization estimates that sepsis affected approximately 49 million people and was associated with about 11 million deaths worldwide in 2017, representing nearly one-fifth of global deaths. In the United States, the CDC reports that at least 1.7 million adults develop sepsis annually, with roughly 350,000 deaths during hospitalization or discharge to hospice.

The sepsis diagnostic landscape spans blood culture, lactate testing, procalcitonin, C-reactive protein, host-response assays, molecular diagnostics, multiplex syndromic panels, antimicrobial susceptibility testing, and clinical decision support tools. Demand is rising as emergency departments, intensive care units, and microbiology laboratories seek faster pathogen identification, earlier risk stratification, and more precise antimicrobial stewardship. This makes accurate, rapid, and workflow-ready sepsis testing essential for improving treatment decisions and reducing avoidable delays.

Transformative Shifts in Sepsis Diagnostics

The sepsis diagnostic landscape is shifting from culture-dependent workflows toward integrated, time-sensitive diagnostic pathways. Conventional blood culture remains essential for pathogen recovery and antimicrobial susceptibility testing, but its turnaround time can delay targeted therapy. Rapid molecular diagnostics, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, host immune-response signatures, and automated laboratory platforms are increasingly used to shorten the interval from suspicion to actionable results.

A second transformation is occurring at the care-delivery level. Sepsis screening is moving beyond the ICU into emergency departments, medical wards, ambulatory escalation pathways, and remote triage programs. Hospitals are prioritizing diagnostic solutions that combine clinical scoring, laboratory biomarkers, electronic health record alerts, and stewardship protocols to reduce inappropriate antibiotic use while supporting early intervention for high-risk patients. The shift is also reinforcing the need for interoperability between laboratory information systems, electronic health records, and point-of-care workflows.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact on sepsis diagnostics by improving risk prediction, workflow prioritization, and clinical decision support. AI-enabled models can analyze electronic health record data, vital signs, laboratory trends, medication history, comorbidities, and microbiology signals to flag deterioration earlier than manual review alone. The strongest applications are not stand-alone replacements for clinicians but assistive systems embedded into validated sepsis protocols.

The opportunity is tied to governance and evidence. Hospitals are demanding transparent model performance, bias monitoring, local validation, human oversight, and integration with laboratory information systems. AI can also support diagnostic stewardship by helping clinicians decide when to order blood cultures, lactate, procalcitonin, molecular panels, or repeat testing, thereby aligning rapid sepsis diagnostics with cost control and antimicrobial stewardship. As regulatory expectations for clinical software mature, explainability, auditability, and real-world monitoring are becoming essential adoption criteria.

Key Regional Insights: Sepsis Diagnostic Adoption

Asia-Pacific is a major sepsis diagnostic adoption region due to expanding hospital capacity, large patient populations, and rising use of automated microbiology and molecular testing in China, India, Japan, South Korea, and Australia. The region's infectious disease burden, growing intensive care infrastructure, and increasing focus on antimicrobial resistance are strengthening demand for rapid pathogen identification and biomarker-based risk assessment. North America remains a mature innovation hub, supported by hospital quality initiatives, CDC sepsis awareness programs, FDA-regulated diagnostic pathways, and strong adoption of rapid pathogen identification technologies across emergency departments, ICUs, and centralized laboratories.

Europe benefits from coordinated antimicrobial resistance strategies, advanced laboratory networks, and strong demand for evidence-based diagnostic stewardship under rigorous in vitro diagnostic and clinical performance expectations. Latin America is expanding access to blood culture automation and critical care diagnostics, with Brazil and Mexico serving as important adoption centers as tertiary hospitals modernize microbiology capabilities. The Middle East is investing in tertiary care infrastructure, digital health, and laboratory modernization, particularly in urban hospital networks, while Africa faces the highest need for scalable, affordable sepsis diagnostics that can operate across resource-variable settings where timely blood culture access, trained personnel, and laboratory connectivity remain uneven.

Key Group Insights Across Strategic Economies

ASEAN markets are advancing sepsis diagnostics through investment in hospital laboratories, infectious disease surveillance, and critical care capacity, although access remains uneven between urban referral centers and rural facilities. The GCC is accelerating uptake through premium hospital systems, digital health programs, and centralized laboratory networks, particularly where sepsis management is integrated into emergency and intensive care pathways. These group-level dynamics highlight the importance of diagnostics that are scalable, interoperable, and adaptable to different levels of laboratory maturity.

The European Union is shaped by regulatory rigor, antimicrobial resistance policy, cross-border health technology assessment, and growing emphasis on diagnostic stewardship within hospital infection management. BRICS countries represent a major clinical-volume opportunity because China, India, Brazil, Russia, and South Africa combine large patient pools with growing demand for cost-effective rapid diagnostics and more resilient laboratory systems. G7 markets lead in clinical validation, reimbursement sophistication, quality-based care pathways, and AI-enabled decision support, while NATO member countries increasingly emphasize resilient diagnostics, infectious disease preparedness, supply chain continuity, and hospital readiness for emerging biological threats.

Key Country Insights in Sepsis Diagnostics

The United States leads adoption of sepsis diagnostic innovation due to high sepsis burden, hospital quality metrics, antimicrobial stewardship requirements, and strong demand for rapid molecular testing and AI clinical decision support. Canada emphasizes standardized care pathways, laboratory quality, and equitable access across provincial health systems, while Mexico and Brazil are expanding hospital-based diagnostics amid rising critical care needs and investment in tertiary care infrastructure. The United Kingdom, Germany, France, Italy, and Spain demonstrate strong demand for antimicrobial stewardship-aligned diagnostics, with Germany and France supported by advanced laboratory infrastructure and the United Kingdom emphasizing protocolized sepsis recognition across acute care settings.

Russia maintains demand for hospital microbiology modernization and broader access to timely pathogen identification, while China and India are among the most important sepsis diagnostic adoption markets due to scale, infectious disease burden, expanding tertiary care, and growing laboratory automation. Japan, Australia, and South Korea show strong adoption potential for automated platforms, rapid pathogen identification, host-response testing, and digital sepsis surveillance, supported by sophisticated hospital systems, robust diagnostic quality standards, and aging populations that elevate sepsis risk. Across these countries, adoption is increasingly influenced by evidence of clinical utility, workflow integration, and the ability to support targeted antimicrobial therapy.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that reduce time to actionable results rather than simply adding test volume. The strongest strategies combine blood culture optimization, rapid molecular diagnostics, biomarker testing, antimicrobial susceptibility workflows, and AI-enabled triage into practical sepsis pathways that emergency physicians, intensivists, infectious disease specialists, and laboratory teams can trust. Solutions should be designed for integration with existing laboratory information systems, electronic health records, and antimicrobial stewardship programs.

Commercial success will depend on demonstrating measurable value: earlier appropriate therapy, reduced unnecessary broad-spectrum antibiotic use, shorter length of stay, improved laboratory productivity, and alignment with sepsis quality programs. Companies should invest in regional evidence generation, reimbursement strategy, cybersecurity for connected diagnostics, user training, and partnerships with hospitals that can validate real-world performance across diverse patient populations. Leaders should also adapt product configurations for resource-variable settings, including simplified workflows, robust sample handling, and clear clinical interpretation.

Research Methodology

This executive summary is developed using a structured secondary-research methodology grounded in verified public health, regulatory, clinical, and market-relevant sources. Key inputs include WHO and CDC sepsis burden data, peer-reviewed literature on sepsis biomarkers and molecular diagnostics, antimicrobial resistance policy documents, regulatory guidance for in vitro diagnostics and software as a medical device, and publicly available hospital quality initiatives.

Insights are synthesized through triangulation across disease burden, technology adoption, laboratory workflow, regional healthcare infrastructure, regulatory maturity, and commercial readiness. Emphasis is placed on evidence-backed interpretation rather than speculative claims, with attention to diagnostic utility, implementation constraints, and the practical requirements of clinicians, microbiologists, payers, and health system decision-makers. The analysis avoids market sizing, share estimates, and forecasts, focusing instead on verified adoption drivers and operational implications.

Conclusion

Sepsis diagnostics are entering a more integrated era defined by speed, accuracy, stewardship, and clinical workflow alignment. While blood culture remains foundational, the field is increasingly shaped by molecular diagnostics, host-response biomarkers, automated microbiology, lactate and procalcitonin testing, antimicrobial susceptibility workflows, and AI-enabled decision support that can help identify high-risk patients earlier.

The next phase of adoption will favor organizations that prove clinical value in real-world settings and adapt solutions to regional healthcare realities. As sepsis continues to impose a major global mortality and economic burden, reliable diagnostics that accelerate evidence-based treatment will remain essential to patient outcomes, hospital performance, antimicrobial resistance control, and health system resilience.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Sepsis Diagnostic Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Analyzers
  • 7.1.2. Point-Of-Care Devices
• 7.2. Reagents & Kits
  • 7.2.1. Biomarker Kits
  • 7.2.2. Culture Media
• 7.3. Software & Services
  • 7.3.1. Consulting Services
  • 7.3.2. Data Management Software

8. Sepsis Diagnostic Market, by Technology

• 8.1. ELISA
  • 8.1.1. Competitive ELISA
  • 8.1.2. Sandwich ELISA
• 8.2. Flow Cytometry
  • 8.2.1. Conventional Flow Cytometry
  • 8.2.2. Imaging Flow Cytometry
• 8.3. NGS
  • 8.3.1. Targeted Sequencing
  • 8.3.2. Whole Genome Sequencing
• 8.4. PCR
  • 8.4.1. Multiplex PCR
  • 8.4.2. Real-Time PCR

9. Sepsis Diagnostic Market, by End User

• 9.1. Ambulatory Care Centers
  • 9.1.1. Clinics
  • 9.1.2. Outpatient Centers
• 9.2. Diagnostic Laboratories
  • 9.2.1. Clinical Laboratories
  • 9.2.2. Reference Laboratories
• 9.3. Hospitals
  • 9.3.1. General Hospitals
  • 9.3.2. Tertiary Care Hospitals

10. Sepsis Diagnostic Market, by Distribution Channel

• 10.1. Direct
• 10.2. Indirect
  • 10.2.1. Distributors
  • 10.2.2. E-Commerce

11. Sepsis Diagnostic Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Sepsis Diagnostic Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Sepsis Diagnostic Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Alifax S.r.l.
• 15.3. Beckman Coulter, Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. bioMerieux SA
• 15.6. Boditech Med Inc.
• 15.7. Bruker Corporation
• 15.8. CytoSorbents Corporation
• 15.9. DiaSorin S.p.A.
• 15.10. EKF Diagnostics
• 15.11. F. Hoffmann-La Roche AG
• 15.12. Immunexpress Inc.
• 15.13. Koninklijke Philips N.V.
• 15.14. McKesson Corporation
• 15.15. Merck KGaA
• 15.16. Molzym GmbH & Co. KG
• 15.17. Nanomix Inc.
• 15.18. Oracle Corporation
• 15.19. QIAGEN N.V.
• 15.20. Response Biomedical Corporation
• 15.21. Seegene Inc.
• 15.22. Siemens Healthineers
• 15.23. T2 Biosystems
• 15.24. Thermo Fisher Scientific, Inc.
• 15.25. Wolters Kluwer N.V.